Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 2/20 | 0.43 |
| ▸ | IKBKB | O14920 | 2/20 | 0.42 |
| ▸ | CHUK | O15111 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 7/20 | 0.38 |
| ▸ | MMP1 | P03956 | 6/20 | 0.38 |
| ▸ | MMP3 | P08254 | 6/20 | 0.38 |
| ▸ | MMP7 | P09237 | 6/20 | 0.38 |
| ▸ | MMP9 | P14780 | 6/20 | 0.38 |
| ▸ | MMP13 | P45452 | 6/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769197 | 0.77 | ADAMTS4 (0.36) | MMP1MMP9MMP13ADAMTS4ALDH1A1 | |
| SCHEMBL6407532 | 0.77 | ADAMTS4 (0.36) | MMP1MMP9MMP13ADAMTS4ALDH1A1 | |
| SCHEMBL6326378 | 0.73 | ADAMTS4 (0.65) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL6326385 | 0.73 | ADAMTS4 (0.65) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL3416060 | 0.72 | MMP2 (0.56) | TDO2MMP2MMP1MMP3MMP7 | |
| SCHEMBL6321461 | 0.72 | MMP2 (0.56) | TDO2MMP2MMP1MMP3MMP7 | |
| SCHEMBL3161450 | 0.72 | MMP2 (0.56) | TDO2MMP2MMP1MMP3MMP7 | |
| SCHEMBL16519484 | 0.71 | CA2 (0.68) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL16519485 | 0.71 | CA2 (0.68) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL4752500 | 0.71 | CA2 (0.68) | MMP2MMP1MMP3MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | TDO2 1426/4885IKBKB 806/4885CHUK 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.